Ru基药物的化学治疗作用机制涉及质膜破坏,使用细胞膜模型可以获得对该过程的有价值的见解。一系列细胞毒性η6-对-异丙基苯并苯并苯二甲酸钌(II)配合物的相互作用,[Ru(η6-对-异丙基甲苯)P(3,5-C(CH3)3-C6H3)3Cl2](1),[Ru(η6-对-异丙基甲苯)P(3,5-CH3-C6H3)3Cl2](2),[Ru(η6-对-异丙基苯并甲苯)P(4-CH3O-3,5-CH3-C6H2)3Cl2](3),和[Ru(η6-对-异丙基甲苯)P(4-CH3O-C6H4)3Cl2](4),使用Langmuir单层作为简化的健康和癌性外叶质膜模型进行检查。癌膜(CM1和CM2)模型包含40%的1,2-二棕榈酰-sn-甘油-3-磷酸胆碱(DPPC)或1,2-二油酰-sn-甘油-3-磷酸胆碱(DOPC),30%胆固醇(Chol),20%1,2-二棕榈酰基-sn-甘油-3-磷酸乙醇胺(DPPE),和10%1,2-二棕榈酰基-sn-甘油基-3-磷酸-1-丝氨酸(DPPS)。同时,健康膜(HM1和HM2)模型由60%的DPPC或DOPC组成,30%Chol和10%DPPE。复合物影响癌性和健康膜模型的表面压力等温线和降低的压缩模量,根据偏振调制红外反射吸收光谱(PM-IRRAS)的数据,与单层的头部和尾部相互作用。然而,这些作用与复合物对癌细胞和健康细胞的毒性无关。多维投影技术表明,复合物(1)引起CM1和HM1单层的显着变化,尽管它对癌细胞的细胞毒性最低,对健康细胞没有毒性。此外,毒性最强的复合物(2)和(4)是对CM2和HM2单层影响最小的复合物。这里的发现支持钌配合物与细胞膜模型中的脂质和胆固醇相互作用,它们的细胞毒活性涉及除膜破坏之外的多方面作用模式。
The mechanism of chemotherapeutic action of Ru-based drugs involves plasma membrane disruption and valuable insights into this process may be gained using cell membrane models. The interactions of a series of cytotoxic η6-p-cymene ruthenium(II) complexes, [Ru(η6-p-cymene)P(3,5-C(CH3)3-C6H3)3Cl2] (1), [Ru(η6-p-cymene)P(3,5-CH3-C6H3)3Cl2] (2), [Ru(η6-p-cymene)P(4-CH3O-3,5-CH3-C6H2)3Cl2] (3), and [Ru(η6-p-cymene)P(4-CH3O-C6H4)3Cl2] (4), were examined using Langmuir monolayers as simplified healthy and cancerous outer leaflet plasma membrane models. The cancerous membrane (CM1 and CM2) models contained either 40 % 1,2- dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 30 % cholesterol (Chol), 20 % 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), and 10 % 1,2-dipalmitoyl-sn-glycero-3-phospho-l-serine (DPPS). Meanwhile, the healthy membrane (HM1 and HM2) models were composed of 60 % DPPC or DOPC, 30 % Chol and 10 % DPPE. The complexes affected surface pressure isotherms and decreased compressional moduli of cancerous and healthy membrane models, interacting with the monolayers headgroup and tails according to data from polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS). However, the effects did not correlate with the toxicity of the complexes to cancerous and healthy cells. Multidimensional projection technique showed that the complex (1) induced significant changes in the CM1 and HM1 monolayers, though it had the lowest cytotoxicity against cancer cells and is not toxic to healthy cells. Moreover, the most toxic complexes (2) and (4) were those that least affected CM2 and HM2 monolayers. The findings here support that the ruthenium complexes interact with lipids and cholesterol in cell membrane models, and their cytotoxic activities involve a multifaceted mode of action beyond membrane disruption.